rabeprazole + amoxicillin

Rabeprazole + amoxicillin is a dual combination therapy consisting of the proton pump inhibitor rabeprazole and the beta-lactam antibiotic amoxicillin. This regimen is primarily used as a first-line treatment for Helicobacter pylori infection, especially in patients who may not tolerate standard triple or quadruple therapies, such as elderly individuals or those with multiple comorbidities. Rabeprazole acts by irreversibly inhibiting the gastric H+/K+ ATPase (proton pump) in parietal cells, thereby suppressing gastric acid secretion and creating a less acidic environment that enhances the efficacy of amoxicillin against H. pylori. Amoxicillin exerts its bactericidal effect by inhibiting bacterial cell wall synthesis during active multiplication of susceptible bacteria[1][7][10]. The combination has demonstrated high eradication rates (up to 90.9%) and favorable safety profiles in clinical studies[1].

Other names

retinoic acid-Shanghai Jiao Tong University School of Medicine-Helicobacter pylori infectionretinoic acidhigh-dose dual therapyHDDTrabeprazole and amoxicillin dual therapy